Welcome to the website of the Malaria in Pregnancy (MiP) Consortium. Since 2010 we have worked across 47 expert institutions worldwide, using standardised methods in sharing research data and information to address the issue of malaria infection during pregnancy.
Annually as many as 125 million pregnancies occur in malaria endemic countries. Infection with malaria in pregnancy can result in pregnancy loss, maternal death, severe maternal anaemia and low infant birth weight which greatly increases the risk of death.
Malaria in pregnancy is responsible for as many as 100,000 children dying needlessly every year. In sub-Saharan Africa, where malaria is endemic in most countries, severe malaria accounts for approximately 10% of maternal deaths, suggesting that an estimated 25,000 maternal deaths could be prevented each year by improved control of malaria in pregnancy.
The MiP consortium, led by the Liverpool School of Tropical Medicine, was established with an initial grant of $30 million from the Bill and Melinda Gates Foundation and throughout its original six-year term has been supported by the European Union and EDCTP along with other funders.
The MiP consortium has met its primary research aims:
Going forward the MiP Consortium will consolidate all of the research from its first phase, putting it into practice in partnership with the national malaria programmes and ministries of health. Work has already begun in Malawi, Mali and Kenya to implement policy changes to ensure that our research can be of benefit to those that need it most, and help to save the lives of mothers and their babies. Our ongoing collaboration with the Worldwide Antimalarial Resistance Network (WWARN) means that the information about our research is readily available to policy makers everywhere, providing a scientific evidence base for prevention strategies and ensuing pregnant women with malaria receive safe and effective malaria treatment.
Our work is nothing without our partners and through the continued and new support of our funders we aim to expand our expertise and ensure that rigorous scientific investigation of the safety and efficacy of antimalarials used during pregnancy continues. Together we will work to end the devastating impact that malaria infection can have on women and their unborn babies throughout endemic countries.